Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2022-05-02 00:00:00 ET · period of report 2022-04-28 · accession 0001209191-22-026483 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-02 | 2022-04-28 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $10.81 | +22.5K | 168.0K | +15% | +$243.2K |
| D | 2022-05-02 | 2022-04-28 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $0.00 | -22.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-28 | M | A | 22,500 | $10.81 | 168,044 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-04-28 | M | D | 22,500 | $0.00 | 0 | D | $10.81 · — to 2022-06-05 | 22,500 Common Stock | (F3) The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. |